Immunosurveillance and therapy of multiple myeloma are CD226 dependent. - Wikidata - awgldk - TriplyDB

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

http://www.wikidata.org/entity/Q35719883

about

Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma Immunosurveillance and immunotherapy of tumors by innate immune cells.Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.MGUS to myeloma: a mysterious gammopathy of underexplored significance.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression NK Cell Exhaustion.Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics Checkpoint Inhibition in Myeloma: Opportunities and Challenges

P2860

Q35834665-D6609515-B695-4783-95D5-0F2CCCFE517D Q36414249-2795B7A4-6D8C-4597-83F8-73C8E82E1E86 Q36471212-878F04DF-5DEA-4A47-AA5F-9563BE67A71B Q37233276-B7E3DC59-85FF-48B2-83FA-51BAFCB27737 Q37517482-340C16AE-1518-4401-80D2-2AACBCFB28D8 Q38708402-4FF8616B-C020-41C0-AE14-B70522AF08D8 Q38875021-962D51E9-6581-4732-823D-442745DF7271 Q38979865-52CC319F-D4E2-49E3-B2F6-2F105A059577 Q39136762-471912DF-8C17-4C0C-9A35-64FF38195422 Q39431541-2DDA478A-084D-4E2A-A370-D82566ACC41C Q41895213-E0C0E009-8B43-4114-8D2E-F61F714CCF96 Q43214125-BE5A06F1-9F50-4E0F-9CF8-544378EC4512 Q49830211-7B7490AD-D597-4BE1-9574-323FBAC91136 Q54212829-6B60C75D-63F7-497A-875D-22F5CD71FC02 Q55332380-775E991F-B7A4-4297-B9E2-A83E7FFA0606 Q56594845-12CF2BB2-1F23-4921-AF14-2315C206B15A Q57491415-ADACAB66-7879-40E9-9D3D-B70EBE92FA2C

P2860

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

http://www.wikidata.org/entity/Q35719883

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

@ast

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

@en

type

label

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

@ast

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

@en

prefLabel

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

@ast

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

@en

P1433

Q35719883-5B7F78FD-E035-485E-B60B-0D7133AC8B28

P1476

Q35719883-51D2DE76-3490-4D72-8A17-33666F88E546

P2093

Q35719883-120A60D1-51A8-4C01-996E-CF9D4872D9EF

Q35719883-1741C91D-993F-4568-9195-3A6467442CE0

Q35719883-1EEB6DDF-5903-4245-8F6E-5EC28BC302F7

Q35719883-57158E5B-8BBA-45DC-B9B0-E455237969ED

Q35719883-5FD1EE53-865E-45C2-87E2-05943C5FFA86

Q35719883-8559029D-EDF5-41B4-BFDF-4F7C7B543EB0

Q35719883-A78FA544-0AC7-47A6-B6E7-894BB904938D

Q35719883-BEBBD9B3-4D8E-4ED1-AC03-9D207328B6A2

Q35719883-C6AD2A63-DB16-4073-8A15-5C65CD0D3A0C

Q35719883-FF84DFEF-AB3E-40CC-9EB8-524E9806E89D

P2860

Q35719883-05E0CF99-3AB5-4CEB-8EF9-243E856ED9D0

Q35719883-07DF18B9-D9AC-4783-B925-8F10EF522315

Q35719883-0A1298F8-54E6-4EB3-B7BB-A47201DFF740

Q35719883-0EB453F4-5A97-43AB-8C16-434AF35E389C

Q35719883-143CC2A0-01C8-48D8-977E-91BA2ACDE235

Q35719883-14466F8C-BF67-4BAB-8E26-18F80B73873C

Q35719883-1555F040-5C4F-4AC3-87FF-8704214A3AA5

Q35719883-190D65F8-E331-45FF-BCAE-C976045E4BD3

Q35719883-199ACF0C-AD78-4199-B08E-C73E58DD5D9F

Q35719883-20CB800F-5E5D-41DA-A527-399917922CCE

P304

Q35719883-55174C24-037B-49E0-A6A0-DF81B5A953BF

P31

Q35719883-958699AD-F45D-4981-AD63-20315E7DE1BB

P356

Q35719883-4B7E2BB1-B15B-4525-AEE5-5976A91AF61A

P407

Q35719883-A4B2B2C4-0294-451F-B327-4EF5FC051781

P433

Q35719883-FDD66193-1895-43AF-9588-B98790AABEF6

P478

Q35719883-22B83177-90F5-4F22-BAC6-8E7B3F37D8F3

P50

Q35719883-14210B5D-BC66-4750-A75D-7BCC34631D2D

Q35719883-64148732-9FD3-4C77-A0E3-1396A9F473AE

Q35719883-9280326F-FA36-47A1-B958-41819180F168

Q35719883-A539F97E-6BDB-41C6-BDCF-240C4E91BE2E

P577

Q35719883-D7A471F0-1AD0-4D4A-9F61-9E97BDE62882

P698

Q35719883-54CC8CF9-AA14-4C95-ACF5-0C75C5BFF5C1

P932

Q35719883-14714DBB-37E2-4819-B1ED-AAA84CAF2376

P356

P1433

Journal of Clinical Investigation

P1476

Immunosurveillance and therapy of multiple myeloma are CD226 dependent.

@en

P2093

Camille Guillerey

http://www.w3.org/2001/XMLSchema#string

David S Ritchie

http://www.w3.org/2001/XMLSchema#string

Geoffrey R Hill

http://www.w3.org/2001/XMLSchema#string

Kim Miles

http://www.w3.org/2001/XMLSchema#string

Marta Chesi

http://www.w3.org/2001/XMLSchema#string

Michele W L Teng

http://www.w3.org/2001/XMLSchema#string

Michelle C R Yong

http://www.w3.org/2001/XMLSchema#string

P Leif Bergsagel

http://www.w3.org/2001/XMLSchema#string

Shin Foong Ngiow

http://www.w3.org/2001/XMLSchema#string

Slavica Vuckovic

http://www.w3.org/2001/XMLSchema#string

P2860

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule

Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)

DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137

P304

2077-2089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI77181

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Ludovic Martinet

Lucas Ferrari de Andrade

P577

2015-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25893601

http://www.w3.org/2001/XMLSchema#string

P932

4463191

http://www.w3.org/2001/XMLSchema#string